Al Jazeera Reporter Defends Peyton Manning HGH Report On Today Show
Al Jazeera’s Deborah Davies went on the Today Show this morning to defend her publication’s reporting of Broncos quarterback Peyton Manning’s alleged connection to HGH shipments. The meat of the interview is above, and you’ll see Davies deftly turn away the hosts’ attempts to poke holes in Al Jazeera’s report.
Some dumb people will watch this interview and say, “Al Jazeera is backpedaling!” simply because Davies reiterates that the documentary never directly accuses Peyton Manning of taking HGH, but instead points out that HGH was repeatedly sent to Manning’s wife, a claim that Manning himself has seemingly acknowledged as fact, under shady circumstances.
Davies isn’t backpedaling here, she’s just being very clear about what exactly her report does and does not say. What it says is that HGH—a scarce drug that is illegal to prescribe off-label and is supposed to be reserved for use by people who suffer from serious conditions like growth hormone deficiency, short bowel syndrome, or HIV wasting—was prescribed off-label to Ashley Manning. Davies can’t come right out and say that the conclusion to be drawn from her report is that Peyton Manning probably used HGH, but she can ask the dummies who host the Today Show to draw their own conclusions.
Why Mark DeRosa Should Never Work in Baseball Again
What Is the College Basketball Crown and Why It’s Struggling
Miami (OH) vs SMU Prediction: Best Bet for NCAA Play-In Game
MLB Home Run Leader Future Picks: Best Bets for 2026 Season
Early NFL Free Agency Winners and Moves That Stand Out
- Top NBA Picks for Today: Thunder vs Magic, Cavs vs Bucks, Nuggets vs 76ers
- Best Future Bets for MLB Strikeout Leader: Crochet, Gilbert, and Cease
- Top NBA Picks Today: Betting Predictions for Monday’s NBA Slate
- Best NCAA Tournament Championship Future Betting Picks Before Selection Sunday
- Sunday NBA Odds and Betting Picks for March 15th
- UFC Vegas 114 Betting Preview: Three Best Bets for Fight Night
- Free NBA Picks for March 14: Three Bets to Target

